Akero Therapeutics (AKRO) Announces Proposed 4.75M Common Share Offering

Akero Therapeutics, Inc. (NASDAQ: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, announced today that it has commenced an underwritten public offering of 4,750,000 shares of its common stock. All of the shares in the offering will be sold by Akero. In addition, Akero expects to grant the underwriters a 30-day option to purchase an additional 712,500 shares of its common stock in the offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC, Jefferies LLC and Evercore Group L.L.C. are acting as joint book-running managers for the proposed offering.

You May Also Be Interested In

• Flowers Foods (FLO) files mixed shelf
• McCormick board member to resign after CFO appointment at Best Buy
• Pinterest CFO resigns, interim replacement named